Stay updated with breaking news from ஜெஃப் லூபர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
binx health, a Boston, MA-based healthcare technology and diagnostics company, closed a Series E financing of $104m. The round was led by OrbiMed, with participation from new investors Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global, and existing investors LSP and Johnson and Johnson Development Corporation, among others. In connection with the financing, Andrew Goldman, Co-founder and Managing Partner of Hildred Capital Management, will join binx health’s Board of Directors. The company intends to use the funds to expand its business reach, ramp manufacturing, scale its proprietary binx io testing instrument and cartridges, expand its sales efforts in the U.S. and abroad, and further build out its proprietary software platform and data infrastructure. ....
binx health Raises $104 Million in Series E Financing - Financing led by OrbiMed, and includes Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global - - Proceeds to support expansion of manufacturing for first-of-kind, FDA-cleared, CLIA-waived binx io rapid molecular diagnostic test, menu expansion, and the company s data and software architecture for its at-home and in-clinic businesses - News provided by Share this article Share this article BOSTON, May 27, 2021 /PRNewswire/ binx health, a healthcare technology and diagnostics company that makes routine testing convenient by enabling access to care where people live, work, study and shop, today announced the closing of a Series E financing of $104 million. The financing was led by OrbiMed, and included other new investors Arrowmark Partners, Hildred Capital Management, Alta Life Sciences and Parian Global, along with existing investors LSP and Johnson and Johnson Develo ....
binx health receives EUA authorizing At-Home COVID-19 sample collection by universities and employers Latest amendment adds important tool for student health and employers in the fight against COVID-19 BOSTON, Dec. 15, 2020 /PRNewswire/ binx health, a first-of-kind population health technology company, announced today that it received an important amendment to its COVID-19 Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), this time for centralized specimen collection kit distribution and retrieval by large partners. The FDA noted in binx s amended EUA that the binx sample collection kit supports a safe return to campuses and other settings (e.g., workplace) where other risk mitigations such as social distancing are less feasible. The FDA added that, since students and employees are co-located in a given setting, the kits can be centrally issued and collected. ....